Epithelial ovarian cancer | Diagnostic criteria (%) | VEGF | HE4 | CA125 | VEGF + HE4 | VEGF + CA125 | HE4+ CA125 | VEGF + HE4 + CA125 |
---|---|---|---|---|---|---|---|---|
I stage | Sensitivity | 44 | 44 | 40 | 76 | 72 | 72 | 84 |
Specificity | 94 | 94 | 92 | 88 | 88 | 88 | 82 | |
PV-PR | 78 | 78 | 71 | 76 | 75 | 75 | 70 | |
PV-NR | 77 | 77 | 75 | 88 | 86 | 86 | 91 | |
II stage | Sensitivity | 48 | 28 | 64 | 64 | 76 | 80 | 96 |
Specificity | 94 | 94 | 92 | 88 | 88 | 88 | 82 | |
PV-PR | 75 | 70 | 80 | 72 | 76 | 76 | 72 | |
PV-NR | 74 | 72 | 83 | 83 | 88 | 89 | 97 | |
III stage | Sensitivity | 72 | 68 | 80 | 88 | 92 | 88 | 96 |
Specificity | 94 | 94 | 92 | 88 | 88 | 88 | 82 | |
PV-PR | 85 | 85 | 83 | 78 | 79 | 78 | 72 | |
PV-NR | 87 | 85 | 90 | 93 | 95 | 93 | 97 | |
IV stage | Sensitivity | 40 | 80 | 84 | 88 | 92 | 92 | 96 |
Specificity | 94 | 94 | 92 | 88 | 88 | 88 | 82 | |
PV-PR | 76 | 86 | 84 | 78 | 79 | 95 | 72 | |
PV-NR | 75 | 85 | 92 | 93 | 95 | 79 | 97 | |
Total group | Sensitivity | 48 | 55 | 67 | 81 | 83 | 83 | 93 |
Specificity | 94 | 94 | 92 | 88 | 88 | 88 | 82 | |
PV-PR | 94 | 94 | 94 | 93 | 93 | 93 | 91 | |
PV-NR | 47 | 51 | 58 | 69 | 72 | 72 | 85 | |
Serous epithelial | Sensitivity | 46 | 70 | 64 | 81 | 77 | 88 | 94 |
Specificity | 94 | 94 | 92 | 88 | 88 | 88 | 82 | |
PV-PR | 89 | 88 | 92 | 88 | 87 | 88 | 95 | |
PV-NR | 71 | 74 | 71 | 81 | 78 | 88 | 93 | |
Endometrioid epithelial | Sensitivity | 50 | 36 | 69 | 71 | 91 | 80 | 95 |
Specificity | 94 | 94 | 92 | 88 | 88 | 88 | 82 | |
PV-PR | 88 | 80 | 91 | 84 | 87 | 86 | 83 | |
PV-NR | 67 | 61 | 77 | 77 | 93 | 83 | 95 |